How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,047 results for

Didanosine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Prior exposure to thymidine analogues and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. (PubMed)

Prior exposure to thymidine analogues and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. Thymidine analogs and didanosine (ddI) have been associated with redistribution of body fat from subcutaneous adipose tissue (SAT) to visceral adipose tissue (VAT), which, in turn, is a risk factor for cardiovascular disease. We explored differences in adipose tissue distribution between people living with HIV (PLWH) with prior exposure

2018 AIDS

2. DIDANOSINE RETINAL TOXICITY. (PubMed)

DIDANOSINE RETINAL TOXICITY. To report nine new cases of retinal degeneration secondary to didanosine toxicity and to summarize the previously reported cases in the literature.This was a multicenter, retrospective, observational case study from seven institutions. Medical records of patients who demonstrated well-demarcated severe midperipheral chorioretinal degeneration and who were previously treated with didanosine therapy were collected and the following information was reviewed: age (...) of chorioretinal degeneration secondary to didanosine toxicity.Nine patients were identified who had findings consistent with peripheral retinal toxicity secondary to didanosine use. Eight of the 9 patients were men, and the median age was 54 years at the time of presentation (mean: 55 years, range, 42-71 years). Snellen distance acuity ranged from 20/20 to 20/32. At least three of the cases in the series demonstrated progression of the peripheral retinal pigment epithelium and photoreceptor atrophy despite

2016 Retina

4. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. (PubMed)

Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. It is unclear whether HIV infection is associated with liver fibrosis in the absence of chronic hepatitis B or C virus (HBV/HCV) coinfection. We compared prevalence of liver fibrosis, noninvasively assessed by the Fibrosis-4 (FIB-4) index, between HIV-infected patients and uninfected controls, and explored determinants of a higher FIB-4 (...) % in HIV-infected and 1.0% in HIV-uninfected participants. After adjustment for age, sex, ethnicity, detectable anti-hepatitis B core/anti-HCV antibodies and excessive alcohol intake, HIV remained significantly associated with higher FIB-4 (+4.2%, P = 0.05). Prior exposure to didanosine, longer duration of a CD4 cell count below 500 cells/μl and a lower CD4 cell count at enrollment were each associated with a higher FIB-4. Markers of immune activation (soluble CD163, activated CD8 T-lymphocytes

Full Text available with Trip Pro

2016 AIDS

5. Noncirrhotic Portal Hypertension in Perinatally HIV-Infected Adolescents Treated with Didanosine-Containing Antiretroviral Regimens in Childhood. (PubMed)

Noncirrhotic Portal Hypertension in Perinatally HIV-Infected Adolescents Treated with Didanosine-Containing Antiretroviral Regimens in Childhood. Noncirrhotic portal hypertension (NCPH) has been reported in HIV-infected adults. Antiretroviral drugs, as well as genetic and thrombophilic predisposition, have been suggested as possible etiologic factors.Clinical data were collected from 6 HIV-infected patients attending the Infectious Diseases Departments at respectively Emma Children's Hospital (...) Academic Medical Centre in Amsterdam, The Thai Red Cross AIDS Research Centre, Bangkok, Imperial College Healthcare NHS Trust, London who were diagnosed with NCPH. All underwent extensive blood analysis, liver ultrasound, liver elastography, esophagogastroduodenoscopy and percutaneous needle liver biopsy for histological evaluation.We describe 6 perinatally HIV-infected adolescents, all female, who developed NCPH after prolonged exposure during childhood to a didanosine-containing antiretroviral

2016 Pediatric Infectious Dsease Journal

6. Didanosine

Didanosine Didanosine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Didanosine Didanosine Aka: Didanosine , ddI , Videx From Related (...) Chapters II. Mechanism Purine analogue Degraded at an acidic pH (all preparations have buffer) III. Pharmacokinetics Crosses the Blood brain barrier Actively excreted by the IV. Efficacy Delays HIV progression to Transiently increases s Partially suppresses p24 antigenemia Patients with HIV disease and < 300 cells Received varying lengths of AZT therapy V. Dosing Didanosine 200 mg PO bid ($186/month) Take on an empty Avoid concurrent (exacerbates toxicity) Take Medications requiring acidic pH 2 hours

2018 FP Notebook

7. Risk of cancer in children exposed to didanosine in utero. (PubMed)

Risk of cancer in children exposed to didanosine in utero. Evaluation of long-term tolerance to antiretroviral exposure during pregnancy is required. An increased risk of cancer has been suggested in children exposed in utero to didanosine.Updated evaluation of cancer incidence in uninfected children exposed to nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in the French perinatal study of children born to HIV+ mothers, by cross-checking with the National Cancer Registry. Associations (...) didanosine. Didanosine accounted for only 10% of prescriptions but was associated with one-third of cancers. In a multivariate analysis, didanosine exposure was significantly associated with higher risk [hazard ratio = 3.0 (0.9-9.8)]. The risk was specifically linked with first-trimester exposure [hazard ratio = 5.5 (2.1-14.4)]. Overall, the total number of cases was not significantly different from that expected for the general population [SIR = 0.8 (0.47-1.24)], but was twice that expected after

Full Text available with Trip Pro

2016 AIDS

8. The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction. (PubMed)

The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction. NRTIs are essential components of HIV therapy with well-documented, long-term mitochondrial toxicity in hepatic cells, but whose acute effects on mitochondria are unclear. As acetaminophen-induced hepatotoxicity also involves mitochondrial interference, we hypothesized that it would be exacerbated in the context of ART.We evaluated the acute effects of clinically (...) relevant concentrations of the most widely used NRTIs, alone or combined with acetaminophen, on mitochondrial function and cellular viability.The purine analogues abacavir and didanosine produced an immediate and concentration-dependent inhibition of oxygen consumption and complex I and III activity. This inhibition was accompanied by an undermining of mitochondrial function, with increased production of reactive oxygen species and reduction of mitochondrial membrane potential and intracellular ATP

Full Text available with Trip Pro

2016 Journal of Antimicrobial Chemotherapy

9. Prevalence of significant liver disease in human immunodeficiency virus-infected patients exposed to Didanosine: A cross sectional study (PubMed)

Prevalence of significant liver disease in human immunodeficiency virus-infected patients exposed to Didanosine: A cross sectional study To identify significant liver disease [including nodular regenerative hyperplasia (NRH)] in asymptomatic Didanosine (DDI) exposed human immunodeficiency virus (HIV) positive patients.Patients without known liver disease and with > 6 mo previous DDI use had liver stiffness assessed by transient elastography (TE). Those with alanine transaminase (ALT) above

Full Text available with Trip Pro

2016 World journal of hepatology

10. Efavirenz Capsule Sprinkle and Liquid Formulations with Didanosine and Emtricitabine in HIV-1-Infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922. (PubMed)

Efavirenz Capsule Sprinkle and Liquid Formulations with Didanosine and Emtricitabine in HIV-1-Infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922. AI266-922 was an open-label, dose-ranging study that assessed the pharmacokinetics, safety and efficacy of efavirenz (EFV) in children (3 months to 6 years).Antiretroviral-naïve and antiretroviral-experienced HIV-1-infected children received once-daily EFV as oral solution or capsule sprinkle plus didanosine and emtricitabine (...) modeling and simulation; however, Food and Drug Administration-approved doses should be used clinically. EFV + didanosine + FTC was efficacious with no new pediatric safety findings reported.

2015 Pediatric Infectious Dsease Journal

11. A Case of Non-Cirrhotic Portal Hypertension Associated With Chronic Didanosine Therapy (PubMed)

A Case of Non-Cirrhotic Portal Hypertension Associated With Chronic Didanosine Therapy A 66-year-old man with HIV and recurrent thromboembolism presented with new-onset ascites with an extensive diagnostic work-up that was unremarkable. He was diagnosed with non-cirrhotic portal hypertension after a liver biopsy revealed mild fibrosis and hepatic venography revealed an elevated hepatic venous pressure gradient. The etiology of portal hypertension was attributed to didanosine therapy, a rare

Full Text available with Trip Pro

2015 ACG case reports journal

12. Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers

Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x (...) × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2014 Clinical Trials

13. Didanosine

Didanosine Didanosine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Didanosine Didanosine Aka: Didanosine , ddI , Videx From Related (...) Chapters II. Mechanism Purine analogue Degraded at an acidic pH (all preparations have buffer) III. Pharmacokinetics Crosses the Blood brain barrier Actively excreted by the IV. Efficacy Delays HIV progression to Transiently increases s Partially suppresses p24 antigenemia Patients with HIV disease and < 300 cells Received varying lengths of AZT therapy V. Dosing Didanosine 200 mg PO bid ($186/month) Take on an empty Avoid concurrent (exacerbates toxicity) Take Medications requiring acidic pH 2 hours

2015 FP Notebook

14. Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial). (PubMed)

Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial). once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine.the ALIZE ANRS 099 trial enrolled 355 adults with plasma HIV RNA levels of <400 copies/mL under a protease inhibitor (...) -based regimen, who were randomized to remain on this regimen or to switch to a once-daily regimen of emtricitabine, didanosine and efavirenz for 48 weeks. An extended 4 year follow-up was available for the 178 patients who switched to the efavirenz-containing regimen, and assessed plasma HIV RNA levels, CD4 cell counts, safety and tolerability.after a median follow-up of 42 months, 121 patients (68%) remained on an efavirenz-based regimen, and 62% and 57% had plasma HIV RNA levels of <400 and <50

Full Text available with Trip Pro

2011 The Journal of antimicrobial chemotherapy

15. Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. (PubMed)

Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. Our aim was to investigate the respective role of statistical methodology and patients' baseline characteristics in the selection of mutations included in genotypic resistance scores.As an example, the FORUM database on didanosine including 1453 patients was used. We split this population into four samples based

Full Text available with Trip Pro

2010 Journal of Antimicrobial Chemotherapy

16. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. (PubMed)

Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. Abacavir and didanosine are nucleoside reverse transcriptase inhibitors (NRTI) widely used in therapy for HIV-infection but which have been linked to cardiovascular complications. The objective of this study was to analyze the effects of clinically relevant doses of abacavir and didanosine on human leukocyte-endothelium interactions and to compare them with those of other (...) NRTIs.The interactions between human leukocytes - specifically peripheral blood polymorphonuclear (PMN) or mononuclear (PBMC) cells - and human umbilical vein endothelial cells were evaluated in a flow chamber system that reproduces conditions in vivo. The expression of adhesion molecules was analyzed by flow cytometry.Abacavir induced a dose-dependent increase in PMN and PBMC rolling and adhesion. This was reproduced by didanosine but not by lamivudine or zidovudine. Both abacavir and didanosine

2010 AIDS

17. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

sex and contraception should be regularly addressed. Giving young people an opportunity to speak with clinic staff on their own is an important part of this process. Appropriate services for adolescents with perinatally acquired HIV infection and the management of transition of their care to adult services are discussed in Section 13. 8. Monitoring on ART • The aim of ART is to achieve an undetectable VL ( nevirapine) Glucose intolerance NRTI thymidine analogues (stavudine, didanosine (...) and zidovudine). Some protease inhibitors (ritonavir-boosted lopinavir; less often atazanavir and fosamprenavir) Lactic acidosis NRTIs, in particular, didanosine and stavudine (enhanced in combination); less commonly zidovudine Granulocytopaenia, neutropaenia and/or anaemia Zidovudine and fosamprenavir Respiratory symptoms Abacavir, lamivudine and zidovudine CNS, central nervous system; SJS, Stevens-Johnson syndrome; EM, erythema multiforme; TEN, toxic epidermal necrolysis; NRTI, nucleoside reverse

2018 The Children's HIV Association

18. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

; low quality of evidence) or Lopinavir/ritonavir 800/200 mg PO once daily (weak recommendation; strong quality of evidence) or Raltegravir HD 1200 mg PO once daily (weak recommendation; very low quality of evidence) NOT recommended Abacavir, didanosine, efavirenz, nevirapine, stavudine Note: FTC = emtricitabine, nPEP = nonoccupational postexposure prophylaxis, PO = per os (orally), TDF = tenofovir disoproxil fumarate. * A thorough medication history (including prescription drugs, supplements

2017 CPG Infobase

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>